We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Erlotinib Shows Early Activity in Liver Cancer

Sep 1, 2005
Volume: 
14
Issue: 
8
  • Lung Cancer, Liver, Gallbladder, and Biliary Tract Cancers

HOUSTON-Erlotinib
(Tarceva) is active in hepatocellular
carcinoma and is well tolerated, according
to interim findings of a phase
II trial at The University of Texas M.D.
Anderson Cancer Center. The results
also suggest that higher expression of
the epidermal growth factor receptor
(EGFR) may be correlated with response
to the drug, said Melanie Thomas,
MD, an assistant professor in the
Department of GI medical oncology at
M.D. Anderson, who discussed the
findings in a poster presentation (abstract
4038).

The trial is designed to accrue 80
patients who are stratified into subgroups
according to high or low expression
of EGFR, the target of erlotinib.
With 33 of 80 patients accrued to
the current trial, 25% had reached the
primary study endpoint of progression-
free survival at 16 weeks. Median
survival was 6 months. There were two
minor responses among 22 evaluable
patients, for a response rate of 9%.
Response did not correlate with other
factors, such as age, sex, presence of
cirrhosis, etiology, or alpha fetoprotein
expression.

EGFR Expression
Survival Trend

Of the eight patients who were progression-
free at 16 weeks, six had high
EGFR expression in tumor cells and
two had low expression. While not
statistically significant, the difference
suggests that expression may be a factor.
"There did seem to be a trend
toward correlation of survival with high
EGFR expression," said Keith E. Stuart,
MD, director of hepatobiliary and
gastrointestinal oncology at Beth Israel
Deaconess Medical Center, Boston,
in discussing the study.

The drug appeared to be safe and
well tolerated. Grade 3 toxicities occurred
in about one-fourth of patientsand included abdominal pain, anemia,
increased bilirubin and AST (aspartate
aminotransferase), skin infection,
vomiting, and diarrhea. All
responding patients developed skin
rash, a common event associated with
erlotinib and other tyrosine kinase inhibitors.

In discussing this trial, Dr. Stuart
noted that it was one of many studies
seeking new approaches to liver cancer.
Hepatocellular carcinoma is oneof the most common causes of death
in the world, he said, and "survival is
uniformly miserable." Five-year survival
rates in the United States have
gone from 2% in the late 1970s to 5%
in the late 1990s. Most patients are not
eligible for resection, he added, and
systemic therapies to date have had
little impact on the disease.

Because hepatocellular carcinomas
are hypervascular tumors, treatments
targeted at proteins that control angiogenesis
are of interest. These include
drugs that target EGFR, such as
erlotinib and gefitinib (Iressa), and
those that target the vascular endothelial
growth factor, such as bevacizumab
(Avastin).

A trial of erlotinib and bevacizumab
combined to treat hepatocellular
carcinoma is being instituted at M.D.
Anderson, Dr. Thomas said, and if the
combination shows efficacy, the next
step could be to combine the two drugs
with chemotherapy.

Related Articles

  • Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
  • Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLC
  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.